Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

December 11, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793899/0/en/Sana-Biotechnology-Highlights-Preclinical-Data-Supporting-Tumor-Control-and-Immune-Evasion-Capabilities-of-Hypoimmune-Modified-Allogeneic-CAR-T-Cells-in-Presentations-at-the-Americ.html

Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission

Validation of novel and fully-human GPRC5D-specific CARs for the development of a HIP-modified allogeneic GPRC5D-directed CAR T cell therapy

Read more at globenewswire.com

Related news for (SANA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.